Daniel Ahn, DO

Assistant Professor

  • 358 Citations
  • 12 h-Index
20022018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 19 Similar Profiles
Biliary Tract Neoplasms Medicine & Life Sciences
Pancreatic Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Survival Medicine & Life Sciences
Cholangiocarcinoma Medicine & Life Sciences
Adenocarcinoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2018

1 Citations

Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer

Ahn, D., Reardon, J., Ahn, C. W., Bupathi, M., Mikhail, S., Wu, C. S. Y. & Bekaii-Saab, T., Apr 15 2018, In : International Journal of Cancer. 142, 8, p. 1671-1675 5 p.

Research output: Contribution to journalArticle

gemcitabine
Biliary Tract Neoplasms
Cisplatin
Survival
Disease-Free Survival
Immune System
Adenocarcinoma
Neoplasms
Therapeutics
Aptitude

Novel immunotherapy strategies for hepatobiliary cancers

Deleon, T. T., Zhou, Y., Nagalo, B. M., Yokoda, R. T., Ahn, D., Ramanathan, R. K., Salomao, M. A., Aqel, B. A., Mahipal, A., Bekaii-Saab, T. & Borad, M. J., Sep 1 2018, In : Immunotherapy. 10, 12, p. 1077-1091 15 p.

Research output: Contribution to journalReview article

Immunotherapy
Neoplasms
Oncolytic Virotherapy
Therapeutics
T-Cell Antigen Receptor
2 Citations

Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma

Deleon, T. T., Ahn, D., Bogenberger, J. M., Anastasiadis, P. Z., Arora, M., Ramanathan, R. K., Aqel, B. A., Vasmatzis, G., Truty, M., Oklu, R., Bekaii-Saab, T. & Borad, M. J., Mar 1 2018, In : Future Oncology. 14, 6, p. 553-566 14 p.

Research output: Contribution to journalReview article

Biliary Tract Neoplasms
Hepatocellular Carcinoma
Neoplasms
Biomarkers
Therapeutics

Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer

Finn, R. S., Ahn, D., Javle, M. M., Tan, B. R., Weekes, C. D., Bendell, J. C., Patnaik, A., Khan, G. N., Laheru, D., Chavira, R., Christy-Bittel, J., Barrett, E., Sawyer, M. B. & Bekaii-Saab, T., May 22 2018, (Accepted/In press) In : Investigational New Drugs. p. 1-7 7 p.

Research output: Contribution to journalArticle

Biliary Tract Neoplasms
Mitogen-Activated Protein Kinase Kinases
Mutation
MEK162
Pharmacokinetics